A Phase 1, First-in-Human, Open-label, Doseescalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 in Subjects with Advanced Solid Tumors
Latest Information Update: 30 Sep 2024
At a glance
- Drugs ASD 141 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Ascendo Biotechnology
- 07 Feb 2024 New trial record